Conducted by researchers in the Texas Medical Center, the peer-reviewed, retrospective case study presents two patients who had clearly defined autoimmune diseases and severe disabilities. Additionally, one pediatric patient had failed standard dysautonomia treatments as well as experienced unsuccessful immunotherapy treatments. The second patient had failed standard treatment for juvenile idiopathic polyarthritis.
"The favorable clinical response in these two young patient warrants further clinical trials using either autologous or allogenic mesenchymal stem cells," the authors wrote in their conclusion.
Dr. Young has extensive academic experience in cell biology, molecular biology, protein science, biochemistry and animal models. Dr. Young is responsible for supervising the production of Celltex's mesenchymal stem cells; evaluating Celltex's stem cells' quality, identity, properties and clinical applications; and she is heavily involved in designing Celltex research, clinical studies and trials, along with physicians in multiple medical centers.
"We are very encouraged by the clinical data obtained in this study, which showed favorable clinical response to Celltex's proprietary stem cell technology in dysautonomia patients," states Dr.Young. "This study is a great representation of Celltex's commitment to leading the United States into the future of regenerative medicine through adult stem cells."
Celltex uses its proprietary technology which isolates, multiplies and banks autologous (one's own) adult mesenchymal stem cells (MSCs) to be used for regenerative therapy for injuries and chronic pain as well as a number of conditions, including vascular, degenerative and autoimmune diseases.
Celltex is registered with the United States Food and Drug Administration as a Human Cell and Tissue Products (HCT/P) establishment that multiplies human cells and cellular products. The company operates in a state-of-the-art laboratory compliant with Current Good Manufacturing Practice (cGMP) standards as recommended by the FDA for the manufacturing of biological products.
To learn more about Celltex, visit www.celltexbank.com
About Celltex Therapeutics Corporation
Celltex is a Houston-based biotechnology company that is leading the United States into the future of adult stem cell therapy with its proprietary technology. Celltex is committed to expanding the use of adult stem cell therapy by licensed physicians, with the goal of securing the future of regenerative medicine in the United States. For more information about Celltex Therapeutics Corporation, please visit www.celltexbank.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celltex-autologous-stem-cell-case-study-published-in-stem-cells-and-development-demonstrates-favorable-response-in-pediatric-patients-300422155.html
|SOURCE Celltex Therapeutics Corporation|
Copyright©2017 PR Newswire.
All rights reserved
Related biology technology :
1. Functional Regeneration of the Macula with Autologous Stem Cells
2. RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
3. R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare
4. Global Stem Cells Group and Kimera Labs Announce Autologous Stem Cell Research Alliance
5. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
6. University of Colorado Cancer Center Study Shows that Bitter Melon Juice Prevents Pancreatic Cancer in Mouse Models
7. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
8. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
9. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
10. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.